AstraZeneca CEO Says Europe Prices Should Be Higher, U.S. Lower

The transcript discusses the impact of new cancer drugs on earnings, highlighting the need for global price adjustments. It also covers the company's preparations for Brexit, focusing on maintaining R&D in Cambridge and addressing manufacturing challenges. The company has invested in duplicating tests in Sweden and increasing safety stock to ensure patient access to medicines.

What preparations has the company made in response to Brexit?

What measures has the company taken to ensure the quality of their products post-Brexit?